Aptose Biosciences INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Aptose Biosciences reports Q1 2026 financial results while navigating a pending acquisition by Hanmi Pharmaceutical.
Aptose Biosciences reports promising clinical data for its lead drug tuspetinib in AML, but faces significant financial challenges including a going concern warning and Nasdaq delisting.
Aptose Biosciences reports promising clinical data for its lead cancer drug, tuspetinib, but faces significant financial challenges including a Nasdaq delisting and substantial doubt about its ability to continue as a going concern.
Aptose Biosciences reports Q1 2025 results with ongoing concerns about its ability to continue as a going concern, despite clinical advancements with its lead drug candidate, tuspetinib.
Aptose Biosciences reported a net loss of $6.95 million for Q3 2024, compared to $11.45 million in Q3 2023, and faces ongoing challenges regarding Nasdaq listing requirements.
Aptose Biosciences reported its Q2 2024 financial results, highlighting ongoing clinical trial progress for tuspetinib while facing significant financial challenges and going concern doubts.
Aptose Biosciences reported a net loss of $9.6 million for the first quarter of 2024, while advancing its clinical programs and addressing financial and compliance hurdles.